The story of Sildenafil presents a complex picture for shareholders. While the initial release generated substantial gains, the end of its intellectual property protection opened the door to off-brand alternatives, https://webnowmedia.com/story7114856/sildenafil-and-big-pharma-a-precarious-opportunity